Diagnosis of Postmenopausal Osteoporosis: Reviews in Endocrine and Metabolic Disorders

Reviews in Endocrine and Metabolic Disorders

Volumn 2, Issue 1, 2001, Pages 23-33

  Shields, Andrew T ^a   Chesnut III, Charles H ^a  

^a UNIVERSITY OF WASHINGTON MEDICAL CENTER   (United States)

Author keywords

Bone mineral density; Densitometry; Diagnosis; Fracture; Markers; Osteoporosis; Post menopausal

Indexed keywords

BIOLOGICAL MARKER;

BONE DENSITY; ENDOCRINE DISEASE; FEMALE; HUMAN; METABOLIC DISORDER; POSTMENOPAUSE OSTEOPOROSIS; RADIOGRAPHY; REVIEW;

BIOLOGICAL MARKERS; BONE DENSITY; ENDOCRINE SYSTEM DISEASES; FEMALE; HUMANS; METABOLIC DISEASES; OSTEOPOROSIS, POSTMENOPAUSAL;

EID: 0035238310     PISSN: 13899155     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1010050823176     Document Type: Review

References (77)

1. Cummings SR, Newitt MC, Browner WS, Stone K, Fox KM, Cauley J, Black D, Vogt TM. Risk factors for hip fractures in white women. N Engl J Med 1995;332:767-773.
2. Miller PD, Bonnick SL, Rosen CJ, Altman RD, Avioli LV, Dequeker J, Felsenberg D, Genant HK, Gennari C, Harper KD, Hodsman AB, Kleerekoper M, Mautalen CA, McClung MR, Meunier PJ, Nelson DA, Peel NF, Raisz LG, Recker RR, Utian WH, Wasnich RD, Watts NB. Clinical utility of bone mass measurements in adults: Consensus of an international panel. The society for clinical densitometry. Semin Arthritis Rheum 1996;25(6):361-372.
3. Miller PD, Bonnick SL, Rosen CJ. Consensus of an international panel on the clinical utility of bone mass measurements in the detection of low bone mass in the adult population. Calcif Tissue Int 1996;58(4):207-214.
4. Hui SL, Slemenda CW, Johnston CC. Age and bone mass as predictors of fracture in a prospective study. Jr J Clin Invest 1988;81(6):1804-1809.
5. Wasnich RD Fracture prediction with bone-mass measurements. In: Genant HK, ed. Osteoporosis Update. Berkeley, CA: University Press, 1987;95-101.
6. Melton LJ 3d, Atkinson EJ, O'Fallon WM, Wahner HW, Riggs BL. Long-term fracture prediction by bone mineral assessed at different skeletal sites. J Bone Miner Res 1993;8(10):1227-1233.
7. Huang C, Ross PD, Wasnich RD. Short-term and long-term fracture prediction by bone mass measurements: a prospective study. J Bone Miner Res 1998;13(1):107-113.
8. Kanis JA, Johnell O, Oden A, Jonsson B, De Laet C, Dawson A. Prediction of fracture from low bone mineral density measurements overestimates risk. Bone 2000;26(4):387-391.
9. Black DM, Arden NK, Palermo L, Pearson J, Cummings SR. Prevalent vertebral deformities predict hip fractures and new vertebral deformities but not wrist fractures. Study of osteoporotic fractures research group. J Bone Miner Res 1999;14(5):821-828.
10. Ross PD, Davis JW, Epstein RS, Wasnich RD. Pre-existing fractures and bone mass predict vertebral fracture incidence in women. Ann Intern Med 1991;1:114(11):919-923.
11. Ettinger MP. When and how to use dual energy X-ray absorptiometry in diagnosis and treatment of osteoporosis. J Fla Med Assoc 1995;82(5):352-357.
12. Miller PD, Zapalowski C, Kulak CA, Bilezikian JP. Bone densitometry: The best way to detect osteoporosis and to monitor therapy. J Clin Endocrinol Metab 1999;84(6):1867-1871.
13. Bouxsein ML, Parker RA, Greenspan SL. Forearm bone mineral densitometry cannot be used to monitor response to alendronate therapy in postmenopausal women. Osteoporosis Int 1999;10(6):505-509.
14. Chrischilles EA, Cooper C, Lane AW, Riggs BL. Perspective. How many women have osteoporosis? Melton LJ ed. J Bone Miner Res 1992;7(9):1005-1010.
15. Melton LJ. How many women have osteoporosis now? 3rd. J Bone Miner Res 1995;10(2):175-177.
16. Looker AC, Johnston CC Jr, Wahner HW, Dunn WL, Calvo MS, Harris TB, Heyse SP, Lindsay RL. Prevalence of low femoral bone density in older U.S. women from NHANES III. J Bone Miner Res 1995;10(5):796-802.
17. Looker AC, Orwoll ES, Johnston CC Jr, Lindsay RL, Wahner HW, Dunn WL, Calvo MS, Harris TB, Heyse SP. Prevalence of low femoral bone density in older U.S. adults from NHANES III. J Bone Miner Res 1997;12(11):1761-1768.
18. Kulak CA, Bilezikian JP. Bone mass measurement in identification of women at risk for osteoporosis. Int J Fertil Womens Med 1999;44(6):269-278.
19. Cummings SR, Black DM, Nevitt MC, Browner W, Cauley J, Ensrud K, Genant HK, Palermo L, Scott J, Vogt TM. Bone density at various sites for prediction of hip fractures. The study of osteoporotic fractures research group. Lancet 1993;9;341(8837):72-75.
20. Bonnick SL. Bone densitometric techniques in modern medicine. In: Rosen C, ed. Osteoporosis: Diagnostic and Therapeutic Principles. Totowa, NJ: Humana; 1996;97.
21. Tsurusaki K, Ito M, Hayashi K. Differential effects of menopause and metabolic disease on trabecular and cortical bone assessed by peripheral quantitative computed tomography (pQCT). Br J Radiol 2000;73(865):14-22.
22. Parfitt AM. Trabecular bone architecture in the pathogenesis and prevention of fracture. Am J Med 1987;26;82(1B):68-72.
23. Jacobs CR. The mechanobiology of cancellous bone structural adaptation. J Rehabil Res Dev 2000;37(2):209-216.
24. Ravn P, Alexandersen P, Mollgaard A. Bone densitometry: A new, highly responsive region of interest in the distal forearm to monitor the effect of osteoporosis treatment. Osteoporosis Int 1999;9(4):277-283.
25. Bonnick SL. Bone Density in Clinical Practice: Application and Interpretation. Humana Press, 1998;57.
26. Bouxsein ML, Parker RA, Greenspan SL. Forearm bone mineral densitometry cannot be used to monitor response to alendronate therapy in postmenopausal women. Osteoporosis Int 1999; 10(6):505-509.
27. Augat P, Fuerst T, Genant HK. Quantitative bone mineral assessment at the forearm: A review. Osteoporosis Int 1998;8(4): 299-310.
28. Groll O, Lochmuller EM, Bachmeier M, Willnecker J, Eckstein F. Precision and intersite correlation of bone densitometry at the radius, tibia and femur with peripheral quantitative CT. Skeletal Radiol 1999;28(12):696-702.
29. Alenfeld FE, Wuster C, Funck C, Pereira-Lima JF, Fritz T, Meeder PJ, Ziegler R. Ultrasound measurements at the proximal phalanges in healthy women and patients with hip fractures. Osteoporosis Int 1998;8(5):393-398.
30. Versluis RG, Petri H, Vismans FJ, van de Ven CM, Springer MP, Papapoulos SE. The relationship between phalangeal bone density and vertebral deformities. Calcif Tissue Int 2000;66(1):1-4.
31. Huang C, Ross PD, Yates AJ, Walker RE, Imose K, Emi K, Wasnich RD. Prediction of fracture risk by radiographic absorptiometry and quantitative ultrasound: A prospective study. Calcif Tissue Int 1998;63(5):380-384.
32. Greenspan SL, Bouxsein ML, Melton ME, Kolodny AH, Clair JH, Delucca PT, Stek M Jr, Faulkner KG, Orwoll ES. Precision and discriminatory ability of calcaneal bone assessment technologies. J Bone Miner Res 1997;12(8):1303-1313.
33. Lochmuller EM, Eckstein F, Kaiser D, Zeller JB, Landgraf J, Putz R, Steldinger R. Prediction of vertebral failure loads from spinal and femoral dual-energy X-ray absorptiometry, and calcaneal ultrasound: An in situ analysis with intact soft tissues. Bone 1998;23(5):417-424.
34. Cheng XG, Nicholson PH, Boonen S, Lowet G, Brys P, Aerssens J, Van der Perre G, Dequeker J. Prediction of vertebral strength in vitro by spinal bone densitometry and calcaneal ultrasound. J Bone Miner Res 1997;12(10):1721-1728.
35. Cepollaro C, Gonnelli S, Pondrelli C, Martini S, Montagnani A, Rossi S, Gennari L, Gennari C. The combined use of ultrasound and densitometry in the prediction of vertebral fracture. Br J Radiol 1997;70(835):691-696.
36. Njeh CF, Boivin CM, Langton CM. The role of ultrasound in the assessment of osteoporosis: A review. Osteoporos Int 1997;7(1):7-22.
37. Rosenthall L, Tenenhouse A, Caminis J. A correlative study of ultrasound calcaneal and dual-energy X-ray absorptiometry bone measurements of the lumbar spine and femur in 1000 women. Eur J Nucl Med 1995;22(5):402-406.
38. Varney LF, Parker RA, Vincelette A, Greenspan SL. Classification of osteoporosis and osteopenia in postmenopausal women is dependent on site-specific analysis. J Clin Densitom 1999;2(3):275-283.
39. Deng HW, Li JL, Li J, Davies KM, Recker RR. Heterogeneity of bone mineral density across skeletal sites and its clinical implications. J Clin Densitom 1998;1(4):339-353.
40. del Puente A, Heyse SP, Mandes MG, Mantova D, Carpinelli A, Nutile G, Oriente P. (III) Epidemiology of osteoporosis in women in southern Italy. Aging (Milano) 1998;10(1):53-58.
41. Lai K, Rencken M, Drinkwater BL, Chesnut CH. Site of bone density measurement may affect therapy decision. 3d Calcif Tissue Int 1993;53(4):225-228.
42. Nelson DA, Malloy R, Kleerekoper M. Prevalence of osteoporosis in women referred for bone density testing: Utility of multiple skeletal sites. J Clin Densitom 1998;1(1):5-11.
43. Bonnick SL. Bone Density in Clinical Practice: Application and Interpretation. Humana Press, 1998;179.
44. Chen Z, Maricic M, Lund P, Tesser J, Gluck O. How the new Hologic hip normal reference values affect the densitometric diagnosis of osteoporosis. Osteoporos Int 1998;8(5):423-427.
45. Watts NB. Understanding the bone mass measurement act. J Clin Densitom 1999;2(3):211-217.
46. Kanis JA, Devogelaer JP, Gennari C. Practical guide for the use of bone mineral measurements in the assessment of treatment of osteoporosis: A position paper of the European foundation for osteoporosis and bone disease. The scientific advisory board and the board of national societies. Osteoporos Int 1996;6(3):256-261.
47. Hill CS, Wolfert RL. The preparation of monoclonal antibodies which react preferentially with human bone alkaline phosphatase and not liver alkaline phosphatase. Clin Chini Acta 1986;186:315-320.
48. Garnero P, Delmas PD. Assessment of the serum levels of bone alkaline phosphatase with a new immunoradiometric assay in patients with metabolic bone disease. J Clin Endocrinol Metab 1993;77:1046-1053.
49. Gomez B, Haugen S, Ardakani S, Cerelli MS, Leung SS, Ju H-SJ, Lundgard R, Daniloff GY, Kung VT. Measurement of bone specific alkaline phosphatase activity in serum using a monoclonal antibody. J Bone Miner Res 1994;9(Suppl 1):S348.
50. Garnero P, Grimaux M, Seguin P, Delmas PD. Characterization of immunoreactive forms of human osteocalcin generated in vivo and in vitro. J Bone Miner Res 1994;9:255-264.
51. Bonde H, Qvist P, Fledelins C, Ris BJ, Christiansen C. Immunoassay for quantifying type I collagen degradation products in urine evaluated. Clin Chem 1994;40:2022-205.
52. Garnero P, Fledelius C, Bonde M, Christiansen C, Delmas PD. Impaired isomerization of type I collagen C-telopeptide in Paget's disease: an index of bone quality. J Bone Miner Res 1996;11(Suppl 1):S370.
53. Bonde M, Garnero P, Fledelius C, Qvist P, Delmas PD, Christiansen C. Measurement of bone degradation products in serum using antibodies reactive with an isomerized form of an 8 amino acid sequence of the C-telopeptide of type I collagen. J Bone Miner Res 1997;12:1028-1034.
54. Farley SR, Hall SL, Ilacas D. Quantification of skeletal alkaline phosphatase in osteoporotic serum by wheat germ agglutinin precipitation, heat inactivation, and a two-site immunoradiometric assay. Clin Chem 1994;4:1749-1756.
55. Garnero P, Grimaux M, Demiaus B, Preaudat C, Sequin P, Delmas PD. Measurement of serum osteocalcin with a human-specific two-site immunoradiometric assay. J Bone Miner Res 1992;7:1389-1398.
56. Pratt BA, Daniloff Y, Duncan A, Robins SP. Automated analysis of the pyridinium crosslinks of collagen in tissue and urine in solid-phase extraction and reversed-phase high-performance liquid chromatography. Anal Biochem 1992;207:168-175.
57. Hanson D, Weis M, Bollen A, Maslan S, Singer F, Eyre D. A specific immunoassay for monitoring human bone resorption: Quantitation of type 1 collagen cross-linked N-telopeptides in urine. J Bone Miner Res 1992;7:1251-1258.
58. Clemens JD, Herrick M, Singer F, Eyre D. Evidence that serum NTX (collagen type 1 N-telopeptides) can act as an immunochemical marker of bone resorption. Clin Chem 1997;43:2058-2063.
59. Looker AC, Bauer DC, Chesnut CH, Gundberg CM, Hochberg MC, Klee G, Kleerekoper M, Watts NB, Bell NH. Clinical use of biochemical markers of bone remodeling-current status and future directions. In Press. Osteoporosis Int 2000.
60. Panteghini M, Pagani F. Biological variation in bone-derived biochemical markers in serum. Scand J Clin Lab Invest 1995;55:609-616.
61. Woitge HW, Schneidt-Nave C, Kissling C, Ledig-Bruckner G, Mayer K, Grauer A. Seasonal variation of biochemical indexes of bone turnover: Results of a population-based study. J Clin Endocrinol Metab 1998;83:68-75.
62. Blumsohn A, Herrington K, Hannon RA, Shao P, Eyre DR, Eastell R. The effect of calcium supplementation on the circadian rhythm of bone resorption. J Clin Endocrinol Metab 1994;79:730-735.
63. Machado A, Hannon R, Eastell R. Monitoring alendronate therapy for osteoporosis. J Bone Miner Res 1999;14:602-608.
64. Eastell R, Mallinak N, Weiss S, Ettinger M, Pettinger M, Cain D, Flessland K, Chesnut C. Biological variability of serum and urinary n-telopeptides of type I collagen in postmenopausal women. J Bone Miner Res 2000;15:594-598.
65. Wichers M, Schmidt E, Bidlingmaier F, Klingmüller. Diurnal rhythm of crosslaps in human serum. Clin Chem 1995;45:1858-1860.
66. Greenspan SL, Dresner-Pollak R, Parker RA, London D, Ferguson L. Diurnal variation of bone mineral turnover in elderly men and women. Calcif Tissue Int 1997;60:419-423.
67. Garnero P, Hausherr E, Chapuy MC, Marcelli C, Grandjean H, Muller C, Cormier C, Breart G, Meunier PJ, Delmas PD. Markers of bone resorption predict hip fracture in elderly women: The EPIDOS prospective study. J Bone Miner Res 1996;11:1531-1538.
68. van Daele PLA, Seibel MJ, Burger H, Hofman A, Grobbee, van Leeuwen JPTM, Birkenhager PC, Pols HAP. Case-control analysis of bone resorption markers, disability, and hip fracture risk: The Rotterdam Study. Br Med J 1996;312:482-483.
69. van Daele PLA. Prediction of osteoporotic fractures. The Rotterdam Study. Ph.D. thesis, Department of Epidemiology and Biostatistics, Erasmus University, Rotterdam, The Netherlands, 1996.
70. Marcus R, Holloway L, Wells B, Greendale G, James MK, Wasilauskas C, Kelaghan J. The relationship of biochemical markers of bone turnover to bone density changes in postmenopausal women: Results from the postmenopausal estrogen/ progestin interventions (PEPI) trial. J Bone Miner Res 1999;14:1583-1595.
71. Bauer DC, Black DM, Ott SM, Santora A, Thompson D, Ennis M, Cummings SR. Biochemical markers predict spine but not hip BMD response to alendronate: The Fracture Intervention Trial (FIT). (Abstract). J Bone Miner Res 1997;12(Suppl 1)1:S150.
72. Chesnut C, Bell NH, Clark GS, Drinkwater BL, English SC, Johnston CC, Notelovitz M, Rosen C, Cain DF, Flessland KA, Mallinak NJS. Hormone replacement therapy in postmenopausal women: Urinary N-telopeptide of type I collagen monitors therapeutic effect and predicts response of bone mineral density. Amer J Med 1997;102:29-37.
73. Greenspan SL, Parker RA, Ferguson L, Rosen HN, Maitland-Ramsey L, Karpf DB. Early changes in biochemical markers of bone turnover predict the long-term response to alendronate therapy in representative elderly women: A randomized clinical trial. J Bone Miner Res 1998;13:1431-1438.
74. Bone H, Downs RW, Tucci JR, Harris ST, Weinstein RS, Licata AA, McClung MR, Kimmel DB, Gertz BJ, Hale E, Polvino WJ. For the Alendronate Elderly Osteoporosis Study Centers dose-response relationships for alendronate treatment in osteoporotic elderly women. J Clin Endocrinol Metab 1997;55:571-576.
75. Garnero P, Shih WJ, Gineyts E, Karpf DB, Delmas PD. Comparison of new biochemical markers of bone turnover in late postmenopausal women in response to alendronate treatment. J Clin Endocrinol Metab 1994;79:1693-1700.
76. Garnero P, Dargent-Molina P, Hans D, Schott AM, Breart G, Meunier PJ, Delmas PD. Do markers of bone resorption add to bone mineral density and ultrasonographic heel measurements for the prediction of hip fracture in elderly women? The EPIDOS prospective study. Osteoporosis Int 1998;8:563-569.
77. National Osteoporosis Foundation. Physicians guide to prevention and treatment of osteoporosis. Belle Meade, NJ: Excerpta Medica, Inc. 1998.